Daihan Pharmaceutical Co.,Ltd. (023910.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	216.6B	208.6B	204.2B	195.9B	184.3B
Cost of Revenue	152.6B	143.8B	134.4B	130.0B	124.0B
Gross Profit	64.0B	64.8B	69.8B	65.9B	60.2B
Operating Expenses
R&D Expense	1.7B	2.2B	1.8B	1.6B	567.9M
SG&A Expense	23.0B	13.4B	13.1B	12.5B	11.8B
General & Admin Expense	9.2B	2.4B	2.3B	2.2B	2.0B
Selling & Marketing Expense	5.6B	11.0B	10.8B	10.3B	9.8B
Other Expenses	9.1B	18.0B	16.8B	16.0B	14.9B
Total Operating Expenses	33.9B	33.6B	31.7B	30.1B	27.3B
Cost and Expenses	186.5B	177.4B	166.1B	160.1B	151.3B
Operating Income (EBIT)	30.1B	31.2B	38.1B	35.8B	33.0B
Non-Operating
Interest Income	2.1B	2.3B	1.5B	87.2M	486.7M
Interest Expense	72.6M	251.8M	1.8M	52.5M	593.4M
Net Interest Income	2.0B	2.0B	1.5B	34.7M	(106.8M)
Other Non-Op Income/Expense	2.8B	2.0B	4.2B	938.2M	483.1M
Non-Operating Income (excl Interest)	(2.1B)	—	(4.2B)	(990.7M)	(1.1B)
EBT (Pre-Tax Income)	32.9B	33.2B	42.3B	36.7B	33.5B
Income Tax Expense	5.4B	5.5B	8.6B	8.3B	8.5B
Bottom Line
Net Income	27.5B	27.6B	33.8B	28.4B	25.0B
Earnings from Cont. Ops	27.5B	27.6B	33.8B	28.4B	25.0B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	27.5B	27.6B	33.8B	28.4B	25.0B
Per Share
Basic EPS	₩4,681	₩4,701	₩5,741	₩4,834	₩4,171
Diluted EPS	₩4,681	₩4,701	₩5,741	₩4,834	₩4,171
Revenue Per Share	₩36,829	₩35,479	₩34,727	₩33,318	₩30,793
Shares
Basic Shares Outstanding	5.9M	5.9M	5.9M	5.9M	6.0M
Diluted Shares Outstanding	5.9M	5.9M	5.9M	5.9M	6.0M
Profitability Metrics
EBITDA	43.3B	40.4B	49.6B	45.4B	43.3B
D&A	11.6B	9.2B	7.3B	8.7B	9.2B
EBIT	31.7B	31.2B	42.3B	36.8B	34.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026